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In this issue of Diabetes and Metabolism Lee et al [1] report the results of the impact 
of visit-to-visit variability in fasting plasma glucose (FPG) on the all-cause mortality of 
persons with type 2 diabetes. This retrospective analysis was a 2-year follow-up of 
3569 persons attending a medical centre in Taiwan. The population was divided into 
groups according to whether visit-to-visit variations in FPG were low, labile 
(decreasing, fluctuating and increasing) or high. The authors conclude, that in 
persons with diabetes, the visit-to-visit variability of FPG referred to as ‘long-term’ 
glucose variability should be maintained as low as possible.  
These results are in broad agreement with previous publications on the long-term 
deleterious impact of glucose variability. The retrospective studies of Muggeo [2], 
Kilpatrick [3] and others [4-7], complemented by a meta-analysis [8] have indicated 
that both in type 1 and type 2 diabetes, high FPG and HbA1c variability were 
associated with a greater risk for adverse clinical outcomes including either micro- or 
macro-vascular complications. However, the authors of the meta-analysis [8] noted 
that most studies suffered from inconsistencies in the definition of HbA1c variability 
considered as ‘long-term’ glycaemic variability. Also the impact of ‘short-term’ 
glycaemic variability, mainly within-day variability, on the development and 
progression of cardiovascular disease has never been established [9]. In an issue of 
Diabetes Care published in 2015, Hirsch [10] and Bergenstal [11] had a Point-
Counterpoint debate. Hirsch argued that acute glucose fluctuations (within-day 
variability) are deleterious and should be a primary target [10]. Bergenstal however, 
argued that preferential consideration should be given to other markers than 
glycaemic variability [11]. The prospective FLAT-SUGAR trial [12] and the latest 
retrospective analysis of the clinical outcomes of the Diabetes Control and 
Complications Trial (DCCT) [9] failed to demonstrate any beneficial impact or 
influence of the ‘short-term’ (within-day glycaemic) variability on surrogate markers of 
cardiovascular disease [12] or on hard outcomes such as the risk for developing 
diabetic complications [9]. However, there arises the question as to whether the 
methodology used in both these analyses was appropriate. In the FLAT-SUGAR 
Study [12] reductions in the short-term glucose variability seen in the exenatide arm 
were not associated with changes in cardio-metabolic risk markers, due possibly to 
the use of insulin in both interventional arms capable of exerting an inhibitory effect 
upon the biological markers of inflammation and activation of the oxidative stress 
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[13]. In the retrospective analysis of the DCCT database, the short-term variability 
relied on quarterly 7-point discontinuous glucose profiles [9], although advocated in 
clinical studies evaluating therapeutic agents [14] it lacks the precision of continuous 
glucose monitoring (CGM) conducted over prolonged periods of time [15-20]. 
Therefore, it remains questionable whether self-monitoring of blood glucose on a 
single day at quarterly time-intervals can be expected to represent chronic glycaemic 
exposure (sustained hyperglycaemia) and its relationship to long-term diabetic 
complications. Presently, despite progress in continuous glucose monitoring (CGM) 
technology, we are still lacking affordable wearable devices, with no constraints, over 
prolonged periods of time such as several months or years. Consequently, it remains 
difficult to prove the existence of a clear relationship between either or both acute 
and long-term glycaemic variations and diabetes related complications. 
In the meantime, many inconsistencies exist in the definition of glycaemic variability 
along with a profusion of surrogate markers which make it difficult to gain a clear 
insight into the potential causative role, in any, of acute exaggerated glycaemic 
fluctuations as risk factors of adverse clinical outcomes. However, in animal studies 
such ‘dangerous waves’ [21] have an adverse effect on vascular endothelial cells, 
due to the activation and perpetuation of oxidative stress, acknowledged as one of 
the key players in the development and progression of diabetic complications [22,23]. 
Currently some of the markers of glycaemic variability are devoted to the assessment 
of short-term glucose variability, standard deviation around the 24-h mean glucose 
value (SD) and coefficient of variation for glucose (CV) [24-26] while others are used 
for assessing the long-term variability ie HbA1c [8, 27]. However, other metrics used 
for assessing short-term glucose variability, are presently too complex for use by 
healthcare professionals and to be integrated into routine care. Included among 
these are  i) the M-index described by Schlichtkrull in 1965 [28], ii) the MAGE (Mean 
Amplitude Glycemic Excursions) and the MODD (Mean of Daily Differences) that 
were developed in the early 1970s by Service and Molnar for assessing the within- 
and between- day glucose variability, respectively [29] and iii) others such as the 
MAG (Mean Absolute Glucose change per hour), CONGA (Continuous Overlapping 
Net Glycemic Action), ADRR (Average Daily Risk Rank) and the LBGI or HBGI (Low 
and High Blood Glucose Index) [24-26]. The LBGI and HBGI, are oriented towards 
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the risk prediction of adverse events such as hypoglycaemia or abnormal acute 
glucose peaks more than towards the specific assessment of glycaemic variability.  
Characterising glycaemic variability includes either the measurement of glucose 
fluctuations or other parameters of glucose homeostasis over a given time-interval. 
This definition therefore covers two distinct types of measurements: i) Firstly, the 
within-and between-day glucose variability determined over short periods of time and 
ii) secondly, the visit-to-visit variability based on serial determinations of either fasting 
plasma glucose or HbA1c at regular monthly or quarterly time-intervals.  
The traditional measure of dispersion and variability for normal distributed data uses 
the standard deviation (SD) and the coefficient of variation (CV) defined as 
([SD/[mean value]) x100% in order to express the CV as a percentage. The daily 
within-day glucose variability, one of the most popular metrics of glycaemic 
variability, is referred to as the SD of glucose. However, the question remains 
whether the SD from a single day is a reliable reflection of the glycaemic variability.  
Consequently physicians should be encouraged to calculate the within-day variability,  
over an extended period of time such as over several consecutive days and then 
average the daily SDs, called the “mean of within-day daily glucose variability” [24, 
25]. The relevance of this assessment should improve with increasing the duration of 
the monitoring period. However, if this period be extended beyond several days, 
especially when now using the new CGM devices, the within-day glucose variability 
needs to be referred to as ‘intermediate’, whilst also defining the time period involved, 
rather than as ‘short-term’ variability. Another method that can be used to estimate 
the daily glucose variability is to calculate the SD of averaged daily blood glucose 
profiles. Such a marker referred to as the “daily SD by average” provides an SD, 
which is usually smaller than the “mean of daily SD” [30], with the underestimation 
becoming more and more marked as soon as the synchrony of glucose patterns from 
day-to-day becomes more and more altered [24]. A large disparity between the mean 
of daily SD for glucose and the daily SD by average reflects a high between-day 
glucose variability.  
An additional parameter of glucose variability can be computed by calculating the 
dispersion of the glucose data at a given time-point over several consecutive days. 
This type of computation, which is provided by the Flash monitoring system of the 
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Free style Libre, using the averaged glycaemic profile (AGP) over 14 days, reports 
the findings as IQRs (Interquartile Ranges). Large time point-to-time point variations 
in the IQRs indicates a loss of synchrony of glucose patterns from day-to-day, i.e. a 
high between-day variability (figure 1) in contrast to small IQR when between-day 
glucose variation is relatively small [24] (figure 1).  
Although we have focused on SD and CV as the metrics of glucose variability and 
deliberately omitted the others that require mathematical skills, interpretation can still 
be somewhat difficult. Therefore, simplifying the findings appears a prerequisite in 
order that any healthcare provider can easily assess and interpret the degree of 
short-term glycaemic variability. According to our most recent research in this field, 
the CV for glucose seems to be the most appropriate index for assessing the mean 
daily within-day variability. As the SD for glucose is usually positively correlated with 
the mean glucose value, the CV renders the assessment of glycaemic variability 
independent of the mean glucose concentration, i.e. on one of the parameters that 
reflects the chronic glycaemic exposure. We have demonstrated that it can be a 
useful and simple tool for separating stable from labile diabetes by setting the cut-off 
value for the CV at 36% [31]. Previously, Hirsch had proposed as an ideal target for 
glycaemic variability an SD calculated from the following formula SD x 3 mean 
glucose, i.e. a  CV < 33%, a value similar to that observed in our study  [32]. 
Reverting to the second type of glycaemic variability, namely the long-term glycaemic 
variability, its assessment is usually based on visit-to-visit measurements of HbA1c 
or FPG which was used by Lee et al in the present issue of Diabetes Metabolism [1]. 
It is suggested that the word ‘long-term variability’ should be only applied to monthly 
measurements of glucose concentration at fasting or casual time-points or to 
quarterly determinations of HbA1c with the subsequent calculation of their SD or 
%CV. However, it should be emphasised that there is currently  no ‘standard’ 
metrics, which partly explains the continued debate relating to the studies that have 
attempted to establish the relationships between the so-called short-term [9] or long-
term glycaemic variability [8] and clinical outcomes. As indicated in a recent 
publication, the long-term variability is probably an “umbrella” for distinct glycaemic 
disorders [33]. It is highly likely that the short-term variability, i.e. the true diabetes 
lability, is mainly dependent on patient’s metabolic intrinsic factors whilst the long-
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term variability is more influenced by many external confounding factors such as poor 
compliance to dietary and pharmacological treatments.  
Whilst bringing all these observations and hypotheses together and returning to the 
key words of our editorial: “definition, profusion and confusion” we currently 
recommend to limit the term “glycaemic variability” to the “mean of within-day daily 
glucose variability” assessed from the mean CV for glucose by averaging each daily 
value over a period of several consecutive days. Utilising a threshold of 36% for the 
CV allows one to discern between stable from labile diabetes [31]. An important fact 
is that unstable diabetes with exaggerated acute glucose fluctuation is associated 
with, and perhaps responsible for an increased risk of hypoglycaemic episodes 
[31,34,35,36].  
In conclusion, the main objectives in the management of diabetes need to include the 
concomitant reduction of both the chronic “ambient” hyperglycaemia and the acute 
daily glucose fluctuations. The availability of newly marketed antidiabetic medications 
such as the class of incretin agents e.g. DPP4 inhibitors and glucagon-like peptide-1 
(GLP-1) receptor agonists, SGLT2 inhibitors and the long-acting insulin preparations 
with flat profiles can help to avoid excessive glucose variability [12,37,38]. Finally, we 
expect that, in the near future, standards of medical care in diabetes will integrate the 
glycaemic variability (for instance a CV ≤36%) as a glycaemic target besides the 
HbA1c ≤7% and the threshold of alert for hypoglycaemia (<70 mg/dL; 3.9 mmol/l) 
[39] (figure 2). 
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Legends of figures 
 
Figure 1: Averaged glucose profiles (AGPs) from two patients with the same 
averaged median interstitial glucose value (165 mg, black dotted line). The 
displayed glucose profiles and medians of glucose (black solid lines) are 14 days 
of CGM data. Shaded dark areas correspond to either IQRs (Interquartile ranges) 
or 10th-90th percentiles.  
The upper panel is the illustration of a patient in whom the synchrony of glucose 
patterns is relatively preserved, i.e. with a small between-day glucose variability 
characterized by small IQRs and small time point-to-point IQR variations.  
The bottom panel is the illustration of a patient with a high loss of synchrony from 
day-to-day in glucose patterns, i.e. a high between-day glucose variability (high 
time-to-time IQR variation) 
Figure 2: Glycaemic targets recommended for HbA1c and glucose alert threshold 
for hypoglycaemia (reference 39) and suggested for glycaemic variability 
expressed as %CV (reference 31). 
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